Keywords: Novartis, Alcon, Eye care, Deal with minority shareholders

Novartis finally reaches agreement with Alcon’s minority shareholders for full control

Article | 15 December 2010

Print This

Ending a long struggle to gain 100% control of eye care specialist Alcon (NYSE: ACL), Swiss drug major Novartis (NOVN: VX) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in